Ovarian Tissue Bioengineering for Fertility Preservation

Abstract

Ovarian tissue bioengineering has emerged as a promising strategy for fertility preservation, particularly for women facing gonadotoxic treatments or premature ovarian insufficiency. This review synthesizes recent advancements, clinical implications, and mechanistic underpinnings of ovarian tissue bioengineering, highlighting its potential to restore both endocrine and reproductive functions. The discourse integrates epidemiological data, current therapeutic strategies, and guideline recommendations, offering a comprehensive perspective for healthcare professionals involved in reproductive medicine and oncofertility.

Introduction

Fertility preservation has become an integral aspect of comprehensive care for women at risk of premature ovarian failure due to cancer therapy, genetic predispositions, or autoimmune disorders. Traditional approaches, such as oocyte or embryo cryopreservation, have limitations, especially in prepubertal girls or when immediate gonadotoxic treatment is required. Ovarian tissue cryopreservation (OTC) and subsequent transplantation offer an alternative; however, challenges such as ischemia-reperfusion injury and follicular loss remain. Bioengineering technologies now aim to overcome these hurdles by recreating the ovarian microenvironment ex vivo, supporting folliculogenesis, and restoring fertility potential. This article explores the scientific foundation, clinical progress, and future directions of ovarian tissue bioengineering for fertility preservation.

Epidemiology / Disease Burden

Globally, the annual incidence of cancer diagnosis among reproductive-aged women is rising, with approximately 10% of cases occurring in women under 40 years. Advances in cancer therapy have improved survival rates, but up to 80% of patients receiving alkylating agents or pelvic irradiation may develop premature ovarian insufficiency (POI). Beyond oncology, genetic syndromes (e.g., Turner syndrome), autoimmune oophoritis, and benign hematological disorders further contribute to the burden of infertility. As survivorship increases, the demand for effective fertility preservation methods is anticipated to grow, underscoring the public health relevance of ovarian tissue bioengineering.

Pathophysiology

The ovary is a complex organ comprised of a heterogeneous population of follicles at various developmental stages, embedded within a specialized stromal matrix. Gonadotoxic insults damage both the oocyte pool and the supporting microenvironment, leading to follicular atresia and stromal fibrosis. The restoration of ovarian function thus requires not only the survival of primordial follicles but also the re-establishment of the stromal-vascular niche that orchestrates folliculogenesis, steroidogenesis, and endocrine homeostasis. Bioengineering approaches leverage biomaterials, scaffolds, and tissue engineering principles to recapitulate these microarchitectural and biochemical cues, aiming to support follicle viability and maturation post-transplantation.

Risk Factors

Major risk factors necessitating fertility preservation include exposure to high-dose chemotherapy, pelvic or total body irradiation, genetic mutations (BRCA1/2, FOXL2, etc.), autoimmune disorders, and iatrogenic injuries (e.g., ovarian surgery). Patient age, baseline ovarian reserve, and underlying comorbidities further modulate risk. Notably, younger patients exhibit higher follicular density, conferring a theoretical advantage for tissue-based preservation but also requiring age-tailored strategies in bioengineering protocols.

Clinical Features

Patients at risk for premature ovarian insufficiency may initially present with irregular menses, oligomenorrhea, or amenorrhea. Biochemical features include elevated gonadotropins (FSH, LH) and low estradiol levels. In oncology settings, clinical features may be masked by the underlying disease or therapy-related side effects, necessitating a high index of suspicion and proactive counseling regarding fertility preservation.

Diagnosis

Assessment of ovarian reserve via serum anti-Müllerian hormone (AMH), antral follicle count (AFC) on transvaginal ultrasound, and basal FSH/LH/estradiol levels is essential for stratifying risk and tailoring fertility preservation strategies. In candidates for ovarian tissue bioengineering, histological assessment of cortical tissue prior to preservation is recommended to quantify primordial follicle density and exclude malignant infiltration, especially in hematological malignancies.

Treatment & Management

Conventional fertility preservation modalities include embryo and oocyte cryopreservation, but these are limited in prepubertal patients and those requiring urgent intervention. Ovarian tissue cryopreservation involves laparoscopic retrieval of cortical strips, cryostorage, and subsequent autotransplantation. Bioengineering interventions enhance this paradigm by integrating decellularized or synthetic scaffolds with isolated follicles or ovarian stromal cells, aiming to mitigate ischemic injury, promote angiogenesis, and facilitate follicle maturation. Autologous transplantation remains the clinical standard, but in vitro maturation (IVM) and artificial ovary constructs represent the cutting edge of translational research.

Recent Advances / Emerging Therapies

Recent progress in ovarian tissue bioengineering encompasses the use of biocompatible scaffolds (e.g., alginate, collagen, fibrin), 3D bioprinting, and decellularized ovarian matrices that preserve native extracellular architecture. These platforms support follicle survival, enable vascularization, and minimize immunogenicity. Preclinical models have demonstrated restoration of endocrine cycles and successful live births following transplantation of engineered ovarian constructs. Advances in microfluidic culture systems and the incorporation of growth factors (VEGF, bFGF) further optimize follicle viability and development. Additionally, gene editing and stem cell technologies promise to expand the follicular pool and enhance graft longevity.

Guideline Recommendations

Major reproductive societies (ASRM, ESHRE) endorse ovarian tissue cryopreservation as a viable, non-experimental option for fertility preservation in selected populations. Guidelines emphasize multidisciplinary counseling, individualized risk assessment, and rigorous preoperative evaluation for malignant contamination. While bioengineering-based therapies are not yet routine in clinical practice, ongoing trials and accumulating safety data are expected to shape future recommendations, particularly for pediatric and high-risk cohorts.

Conclusion

Ovarian tissue bioengineering represents a transformative advance in fertility preservation, with the potential to overcome longstanding challenges in oncofertility and reproductive endocrinology. By integrating biomaterial science, tissue engineering, and reproductive biology, these approaches offer hope for restoring both fertility and endocrine health in women facing premature ovarian failure. Continued research, clinical validation, and interdisciplinary collaboration will be critical in translating these innovations to standard care and expanding reproductive options for affected patients.